Welcome to our dedicated page for Lantern Pharma SEC filings (Ticker: LTRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lantern Pharma Inc. (NASDAQ: LTRN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as an AI-driven, clinical-stage oncology and pharmaceutical preparation manufacturing issuer. Through documents filed with the U.S. Securities and Exchange Commission, investors can review how Lantern reports its financial condition, governance decisions, and material events related to its RADR® AI platform and oncology drug pipeline.
Lantern files annual reports on Form 10-K and quarterly reports on Form 10-Q that describe its business model, risk factors, clinical programs such as LP-184, LP-284, and LP-300, and the role of its RADR® artificial intelligence and machine learning platform in oncology drug discovery and development. Current reports on Form 8-K disclose specific material events, including quarterly financial results, at-the-market equity offering agreements, changes to bylaws, board appointments, and outcomes of annual stockholder meetings, such as director elections and equity incentive plan matters.
Proxy materials, including definitive proxy statements on Schedule 14A, outline Lantern’s corporate governance structure, proposals submitted to stockholders, and details on topics like the repricing of stock options under its equity incentive plan or the ratification of independent auditors. These filings help investors understand how Lantern’s board and management approach capital structure, executive compensation, and shareholder rights as the company advances its AI-enabled oncology strategy.
On Stock Titan, Lantern’s SEC filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify discussion of the RADR® platform, clinical trial progress, regulatory designations, and financing arrangements. Users can monitor real-time updates from EDGAR, review historical filings for context on LTRN’s evolution, and examine governance and compensation disclosures alongside clinical and platform milestones. This page is a central reference for anyone analyzing Lantern Pharma’s regulatory record, from long-form 10-K narratives to focused 8-K announcements.
Lantern Pharma Inc. director David S. Silberstein reported receiving two grants of stock options to buy the company’s common stock. On January 9, 2026, he was awarded 25,000 stock options with an exercise price of $3.49 per share under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. These options vest in equal monthly installments over 24 months starting February 9, 2026.
On the same date, he also received an additional 17,307 stock options with the same $3.49 exercise price under the same plan. This second grant vests in equal monthly installments over 12 months beginning on February 9, 2026. Both grants are held directly by Silberstein and represent compensation in the form of equity incentives rather than an open‑market purchase.
Lantern Pharma (LTRN) reported administrative updates via Form 8-K related to third-quarter communications. The company will release financial results for the quarter ended September 30, 2025 and host a conference call and live webinar on November 13, 2025. A press release is furnished as Exhibit 99.1 and an investor presentation as Exhibit 99.2. These materials are furnished, not filed, under the Exchange Act, so they are not subject to Section 18 liability or automatically incorporated into other filings.
Lantern Pharma (LTRN) filed its Q3 2025 10‑Q, reporting a net loss of $4,177,423 for the quarter and $13,045,221 for the nine months ended September 30, 2025. Operating expenses fell year over year as research and development declined to $2,436,971 in Q3 (from $3,716,646), while general and administrative rose to $1,912,829. Interest income was $100,921 and other income, net was $71,456.
Cash and cash equivalents were $8,389,486 and marketable securities were $3,973,090 at September 30, 2025. Working capital was approximately $9,421,000. Management states that existing cash, cash equivalents, and marketable securities are expected to fund operations until approximately late June 2026 to mid August 2026, and the filing raises “substantial doubt” about the company’s ability to continue as a going concern without substantial additional funding.
To bolster liquidity, Lantern entered an at‑the‑market program of up to $15,530,000. In Q3, it sold 212,444 shares for gross proceeds of $989,061 and paid $29,672 in commissions; from October 1 to the report date, it sold an additional 144,204 shares for gross proceeds of $634,333, with $19,030 in commissions.
Lantern Pharma Inc. filed a Form 8-K reporting voting tallies for one or more matters. The record shows totals including 5,189,274 votes and several vote-category counts such as 2,212,199, 2,214,833, 2,213,670, 2,213,088, and smaller counts listed as Against 758,870, Against 43,732, and Abstain 29,603 and 26,426. The filing names Lantern Pharma Inc. as a Delaware corporation and is signed by David R. Margrave, Chief Financial Officer.
Lantern Pharma (LTRN) director Vijay Chandru amended two outstanding stock options on 09/19/2025, replacing earlier awards with new options priced at $5.04 per share. The original options were granted on 06/15/2020 (9,135 underlying shares, originally $15 exercise price, expiration 06/14/2030) and 11/04/2021 (3,200 underlying shares, originally $10.32 exercise price, expiration 11/03/2031). The amendments cancelled the old options and granted replacement options covering the same share amounts, leaving Mr. Chandru with options for a total of 12,335 underlying shares exercisable under the stated expirations.
Panna Sharma, President & CEO and a director of Lantern Pharma Inc. (LTRN), amended an outstanding stock option originally granted on 06/15/2020. The amendment, recorded with a transaction date of 09/19/2025, canceled the prior option with a $15 exercise price covering 76,628 underlying shares and replaced it with a new option covering the same 76,628 shares at a reduced exercise price of $5.04. The option retains its original exercisability and expiration schedule (vested schedule described in the filing) and the replacement option shows 76,628 shares beneficially owned following the amendment. The form is signed by Ms. Sharma on 09/22/2025.
Kishor G. Bhatia, Chief Scientific Officer of Lantern Pharma Inc. (LTRN), filed a Form 4 reporting amendments to previously granted stock options. The filing shows two option amendments: a June 15, 2020 option was cancelled and replaced with a $5.04 exercise-price option covering 52,200 shares exercisable through 06/14/2030; a October 29, 2021 option was cancelled and replaced with a $5.04 exercise-price option covering 17,400 shares exercisable through 10/28/2031. After the replacements, Mr. Bhatia beneficially owns 52,200 and 17,400 underlying common shares for the respective options.
D. Jeffrey Keyser, a director of Lantern Pharma Inc. (LTRN), reported amendments to two outstanding stock options on a Form 4 covering transactions dated 09/19/2025. Each amendment cancelled an "old" option and granted a replacement option with a reduced exercise price while retaining the original grant dates and expiration dates. The June 15, 2020 option for 9,135 shares was changed from a $15.00 exercise price to $5.04 and remains exercisable through 06/14/2030. The November 4, 2021 option for 3,200 shares was changed from a $10.32 exercise price to $5.04 and remains exercisable through 11/03/2031. Both options vest on the original monthly 36-month schedules.
Lantern Pharma director and Chief Financial Officer David R. Margrave reported amendments to two previously granted stock options that reduced the exercise prices and replaced the canceled options with new options. One option originally granted June 15, 2020 for 78,300 shares was canceled and replaced with a new option exercisable at $5.04, exercisable through 06/14/2030, resulting in a held position of 78,300 underlying shares. A second option originally granted October 29, 2021 for 26,100 shares was canceled and replaced with a new option exercisable at $5.04, exercisable through 10/28/2031, resulting in a held position of 26,100 underlying shares. The filing is limited to these option amendments and the reporting person’s relationship as Director and Chief Financial Officer.
Lantern Pharma Inc. (LTRN): Director David S. Silberstein reported amendments to two outstanding stock options on 09/19/2025 that reduced the exercise prices and replaced the prior options. The first option originally granted 06/15/2020 (exercise price $15) for 9,135 shares was cancelled and replaced with a $5.04 option exercisable through 06/14/2030, leaving 9,135 underlying shares beneficially owned. The second option originally granted 11/04/2021 (exercise price $10.32) for 3,200 shares was cancelled and replaced with a $5.04 option exercisable through 11/03/2031, leaving 3,200 underlying shares beneficially owned. The filings note standard monthly vesting schedules for each original grant and the form is signed 09/22/2025.